8-K: CONMED Reports Q1 2026 Results, Raises Full-Year Outlook

CONMED Corporation announced first quarter 2026 financial results, with sales down 1.3% year-over-year due to product line exits, but raised its full-year organic revenue growth outlook.

Summary

• CONMED Corporation reported first quarter 2026 sales of $317.0 million, a decrease of 1.3% year-over-year (2.9% in constant currency).
• This sales decrease was primarily driven by a $15.5 million reduction from the exit of certain GI products.
• Domestic revenue declined 5.8%, while international revenue increased 4.7% as reported.
• Diluted net earnings per share (GAAP) were $0.45, up from $0.19 in Q1 2025.
• Adjusted diluted net earnings per share (non-GAAP) were $0.89, down from $0.95 in Q1 2025.
• The company is raising its full-year 2026 organic revenue growth outlook to approximately 5.0% to 6.5% on a constant currency basis, excluding GI products.
• Full-year reported revenue is now expected to be between $1.350 billion and $1.375 billion.
• Full-year adjusted diluted net earnings per share are reaffirmed in the range of $4.30 to $4.45.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive result, as the company raised its full-year revenue outlook despite a reported year-over-year sales decline in the quarter due to strategic product exits.

Positives

• Raised full-year 2026 organic revenue growth outlook to 5.0%-6.5% (constant currency, excluding GI products).
• Diluted net earnings per share (GAAP) increased to $0.45 from $0.19 in the prior year's first quarter.
• International revenue increased 4.7% year-over-year as reported.
• Management stated that first quarter performance delivered revenue and adjusted earnings ahead of expectations.
• Gross profit margin improved to 57.9% from 55.3% in the prior year's first quarter.
• Income from operations increased to $25.4 million from $16.0 million in the prior year's first quarter.

Negatives

• Total sales decreased 1.3% year-over-year ($317.0 million vs. $321.3 million).
• Sales were negatively impacted by a $15.5 million decrease from the exit of certain GI products.
• Domestic revenue decreased 5.8% year-over-year.
• Adjusted diluted net earnings per share (non-GAAP) decreased to $0.89 from $0.95 in the prior year's first quarter.
• The company anticipates higher-than-previously anticipated interest expense due to debt refinancing.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Factors that could cause actual results to differ include those discussed in the Company's Annual Report on Form 10-K and other SEC filings.
• The exit of certain GI products is impacting current sales figures.
• Potential for unfavorable foreign exchange impacts, although the outlook now includes a slightly more favorable estimate.

Future Outlook

Management is raising its outlook for full-year 2026 organic revenue growth on a constant currency basis to approximately 5.0% to 6.5%, excluding gastroenterology products. Full-year reported revenue is now expected to be between $1.350 billion and $1.375 billion. The company reaffirms its full-year 2026 adjusted diluted net earnings per share outlook of $4.30 to $4.45, noting that stronger underlying operating performance is largely offset by higher anticipated interest expense from debt refinancing.

Management Comments

• "Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations," said Patrick J. Beyer, CONMEDs President and Chief Executive Officer.
• "We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair."

Industry Context

StockSavvy.ai notes that CONMED's focus on higher-growth, higher-margin areas like minimally invasive surgery and orthopedic soft tissue repair aligns with broader industry trends favoring specialized medical technologies. The impact of product line exits, particularly in gastroenterology, highlights the strategic shifts occurring within the medical device sector as companies rationalize portfolios to focus on core competencies.

Stakeholder Impact

• Shareholders: The raised full-year revenue outlook may be viewed positively, but the decrease in adjusted EPS for the quarter and increased interest expense could temper enthusiasm.
• Employees: Continued focus on higher-growth areas may lead to resource allocation shifts within the company.
• Suppliers/Creditors: The company's debt refinancing plans could impact its debt structure and interest obligations.

Next Steps

• Management will host a conference call on April 29, 2026, at 4:30 p.m. ET to discuss Q1 2026 results.
• The company plans to refinance its debt during 2026, which is expected to increase interest expense.
• Continued concentration of resources and investment on higher-growth, higher-margin areas.

Key Dates

Recommendation

The company raised its full-year revenue outlook, indicating positive momentum in core business segments. However, the reported year-over-year sales decline in the quarter, driven by strategic product exits, and a decrease in adjusted EPS compared to the prior year, alongside anticipated higher interest expenses, warrant a cautious 'hold' rating until the impact of these factors becomes clearer.

Keywords

CONMED Corporation, 8-K Filing, Q1 2026 Earnings, Medical Technology, Financial Results, Revenue Growth, Earnings Per Share, Surgical Devices